Precision BioSciences Inc

Financials

Flusso di cassa derivante dalle attività operative -87.39 M-10.85 M-45.75 M-84.11 M-58.45 M-65.84 M -65.84 M Flussi di cassa derivanti dalle attività di investimento -5.03 M-5.8 M-3.32 M5.83 M-215 K-634 K -634 K Liquidità derivante dalle attività di finanziamento 1.33 M70.52 M94.98 M5.39 M50.45 M95.16 M 95.16 M Liquidità libera -92.42 M-15.91 M-49.07 M-86.07 M-58.7 M-65.93 M -65.93 M

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences Inc

Notizie

Should You Buy Precision BioSciences (DTIL) After Golden Cross?

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18

Jones Trading conferma il rating su Precision BioSciences dopo il design dello studio DMD

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Jefferies riduce il target di prezzo di Precision BioSciences sulla valutazione

Jefferies cuts Precision BioSciences stock price target on valuation

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences ottiene brevetti per il programma epatite B

Precision BioSciences receives patent allowances for hepatitis B program

Precision BioSciences presenta dati preclinici sulla terapia per la DMD

Precision BioSciences presents preclinical data on DMD therapy

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates